MAGEB17

Across TCGA pan-cancer cohorts, MAGEB17 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of MAGEB17’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where MAGEB17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MAGEB17 is over-expressed in tumor.

LIHC, COAD, and UCEC are the cancer types where MAGEB17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAGEB17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	All	+1.100	<.001	9	view →
COAD	Female	All	+1.675	<.001	8	view →
UCEC	All	IV	+0.525	.004	8	view →
BRCA	All	All	+0.309	.012	6	view →
KICH	All	II,III,IV	+0.287	.005	5	view →
HNSC	All	All	+0.149	.008	5	view →
KIRC	All	All	+0.110	.001	4	view →
LUSC	All	All	+0.288	.009	2	view →
PRAD	All	All	+0.270	.002	2	view →
ESCA	All	II,III,IV	+0.050	.037	2	view →
READ	All	All	+0.536	.035	1	view →
LUAD	Male	All	+0.198	.041	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

MAGEB17–LIHC

Open the LIHC breakdown →